FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaUğur Şahin, S. Al-Batran, Christoph Huber et al.|Annals of Oncology|2021Cited by 357
Caveolin-1 Is Down-Regulated in Human Ovarian Carcinoma and Acts as a Candidate Tumor Suppressor GeneKai Wiechen, Christine Sers, Luda Diatchenko et al.|American Journal Of Pathology|2001Cited by 279
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO studyÖ. Türeci, Martin Schüler, Uğur Şahin et al.|Annals of Oncology|2019Cited by 244
Down-Regulation of Caveolin-1, a Candidate Tumor Suppressor Gene, in SarcomasKai Wiechen, Ulrike Schneider, Christine Sers et al.|American Journal Of Pathology|2001Cited by 168
Gene expression profiling in RAS oncogene-transformed cell lines and in solid tumors using subtractive suppression hybridization and cDNA arraysChristine Sers, Reinhold Schäfer, Oleg Tchernitsa et al.|Advances in Enzyme Regulation|2002Cited by 21